Date of Publication: 05-Feb-2026 INTELLIGENCE OVERVIEW The U.S. Food and Drug Administration (FDA) has announced its intent to take regulatory action against non-FDA-approved GLP-1 drug products, including certain compounded versions…
Date of Publication: 05-Feb-2026 (Official Gazette) INTELLIGENCE OVERVIEW Agency: Ministry of Health & Family Welfare – India/ The Gazette of India The Ministry of Health and Family Welfare (MoHFW), India,…
Date of Publication: 02-Feb-2026 INTELLIGENCE OVERVIEW Agency: Central Drugs Standard Control Organization - India/ Ministry of Health & Family Welfare - India The Ministry of Health and Family Welfare (MoHFW),…
Date of Publication (Latest update): 05-Feb-2026 INTELLIGENCE OVERVIEW The European Medicines Agency (EMA) has published an updated data protection notice for EudraVigilance (Human), clarifying how personal data are processed within…
Date of Publication: 05-Feb-2026 INTELLIGENCE OVERVIEW The EMA’s list of new human medicines under evaluation (February 2026) offers an early view into the next wave of therapies moving toward EU…
Date of Publication: 01-Feb-2026 INTELLIGENCE OVERVIEW Agency: US FDA The U.S. Food and Drug Administration (FDA) has launched the PreCheck Pilot Program, an initiative designed to modernize regulatory oversight of sterile pharmaceutical…
Date of Publication: 29-Jan-2026 INTELLIGENCE OVERVIEW Agency: US FDA Regulatory authorities have issued updated guidance on Clinical Decision Support (CDS) software, clarifying how such tools are regulated when used to support healthcare…
Date of Publication: 02-02-2026 INTELLIGENCE OVERVIEW Agency: European Medicines Agency (EMA) The European Medicines Agency (EMA) has published a reflection paper on the qualification of non-mutagenic impurities, providing scientific guidance on…
Date of Publication: 30-01-2026 INTELLIGENCE OVERVIEW Agency: European Medicines Agency (EMA) The European Medicines Agency (EMA) has released a draft reflection paper outlining scientific principles for the qualification and control of…
INTELLIGENCE OVERVIEW The European Medicines Agency (EMA) has issued a Validation Checklist for Type II (non)clinical variations, defining the mandatory documentation required for successful validation of post-authorisation variation applications. Date…